JP2020505049A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505049A5
JP2020505049A5 JP2019541188A JP2019541188A JP2020505049A5 JP 2020505049 A5 JP2020505049 A5 JP 2020505049A5 JP 2019541188 A JP2019541188 A JP 2019541188A JP 2019541188 A JP2019541188 A JP 2019541188A JP 2020505049 A5 JP2020505049 A5 JP 2020505049A5
Authority
JP
Japan
Prior art keywords
seq
recombinant adenovirus
cancer
site
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/016032 external-priority patent/WO2018140973A1/en
Publication of JP2020505049A publication Critical patent/JP2020505049A/ja
Publication of JP2020505049A5 publication Critical patent/JP2020505049A5/ja
Pending legal-status Critical Current

Links

JP2019541188A 2017-01-30 2018-01-30 複数トランスジーン組み換えアデノウイルス Pending JP2020505049A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762452342P 2017-01-30 2017-01-30
US62/452,342 2017-01-30
US201762520945P 2017-06-16 2017-06-16
US62/520,945 2017-06-16
PCT/US2018/016032 WO2018140973A1 (en) 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus

Publications (2)

Publication Number Publication Date
JP2020505049A JP2020505049A (ja) 2020-02-20
JP2020505049A5 true JP2020505049A5 (cg-RX-API-DMAC7.html) 2021-03-11

Family

ID=62978741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541188A Pending JP2020505049A (ja) 2017-01-30 2018-01-30 複数トランスジーン組み換えアデノウイルス

Country Status (12)

Country Link
US (1) US20190352616A1 (cg-RX-API-DMAC7.html)
EP (1) EP3574090A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020505049A (cg-RX-API-DMAC7.html)
KR (1) KR20190128634A (cg-RX-API-DMAC7.html)
CN (1) CN110741080A (cg-RX-API-DMAC7.html)
AU (1) AU2018213417A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019015600A2 (cg-RX-API-DMAC7.html)
CA (1) CA3052090A1 (cg-RX-API-DMAC7.html)
IL (1) IL268291A (cg-RX-API-DMAC7.html)
MX (1) MX2019008921A (cg-RX-API-DMAC7.html)
SG (1) SG11201906973TA (cg-RX-API-DMAC7.html)
WO (1) WO2018140973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
JP7245175B2 (ja) * 2017-05-24 2023-03-23 エピセントアールエックス,インコーポレイテッド 抗脈管形成アデノウイルス
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
US20250177509A1 (en) * 2020-07-06 2025-06-05 Jiaxing Anyu Biotechnology Co., Ltd Recombinant adenovirus vaccine for african swine fever and method for constructing same
WO2022246646A1 (zh) * 2021-05-25 2022-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
CN113249342B (zh) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100896483B1 (ko) * 2007-07-13 2009-05-08 연세대학교 산학협력단 Il-12 및 4-1bbl을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
DK3029144T3 (da) * 2009-03-02 2019-10-21 Univ California Tumorselektive adenovirus e1a- og e1b-mutanter
RU2612788C2 (ru) * 2010-03-23 2017-03-13 Интрексон Корпорейшн Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение
CA2812093A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
AU2013214776B2 (en) * 2012-02-02 2017-11-09 Board Of Regents, The University Of Texas System Adenoviruses expressing heterologous tumor-associated antigens
CA2909432C (en) * 2013-04-18 2025-11-18 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
JP6764859B2 (ja) * 2014-09-24 2020-10-07 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍崩壊性腫瘍ウイルスおよび使用の方法
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2020505049A5 (cg-RX-API-DMAC7.html)
JP2020516293A5 (cg-RX-API-DMAC7.html)
Ding et al. Epithelial‐to‐mesenchymal transition of murine liver tumor cells promotes invasion
JP2020521470A5 (cg-RX-API-DMAC7.html)
JP2019531728A5 (cg-RX-API-DMAC7.html)
Pease et al. Oncolytic viral therapy for mesothelioma
CN108635380A (zh) 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
RU2016120618A (ru) Онколитический hsv-вектор
JP2020516277A5 (cg-RX-API-DMAC7.html)
Yoon et al. CRISPR-Cas12a with an oAd induces precise and cancer-specific genomic reprogramming of EGFR and efficient tumor regression
EP1678193B1 (en) Hepatocellular carcinoma specific promoter and uses thereof
Eltahir et al. Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer
Chen et al. Contribution of tumor heterogeneity in a new animal model of CNS tumors
Nakajima et al. Family with sequence similarity 107: A family of stress responsive small proteins with diverse functions in cancer and the nervous system
Ito et al. Genomic and transcriptional alterations of cholangiocarcinoma
CN102796709A (zh) 肝癌特异性基因-病毒及其应用
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
JP2025038139A5 (cg-RX-API-DMAC7.html)
RU2011136280A (ru) HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
Riederer et al. Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease
WO2020011754A1 (en) Chimeric vaccinia viruses
Nault et al. AAV2 and hepatocellular carcinoma
CN103484462A (zh) Survivin启动子调控CD基因的重组腺病毒载体构建及其应用
RU2018115534A (ru) Противоопухолевая композиция
CN101671666A (zh) 用于恶性肿瘤基因治疗的增殖和肿瘤细胞特异性基因操纵系统